An internal standard for the quantification of hydralazine
Related Products
Unlabeled Version(s)
23121Hydralazine (hydrochloride)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Hydralazine-d4 (hydrochloride)

Item No. 30765

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-hydrazinyl-phthalazine-5,6,7,8-d4, monohydrochloride
CAS Number
2749234-32-8
Synonyms
  • 1-Hydrazinophthalazine-d4
Molecular Formula
C8H4D4N4 • HCl
Formula Weight
200.7
Purity
≥99% deuterated forms (d1-d4)
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: solubleMethanol:Water (1:1): soluble
SMILES
NN=C1NN=CC2=C1C([2H])=C([2H])C([2H])=C2[2H].Cl
InChi Code
InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H/i1D,2D,3D,4D;
InChi Key
ZUXNZUWOTSUBMN-FOMJDCLLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $528

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Hydralazine-d4 is intended for use as an internal standard for the quantification of hydralazine (Item No. 23121) by GC- or LC-MS. Hydralazine is an orally bioavailable vasodilator and antihypertensive agent.1 It decreases DNA methylation in Jurkat cells at a concentration of 10 μM and inhibits extracellular and intracellular production of reactive oxygen species (ROS) in rat macrophages activated by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) at a concentration of 100 μM.2,3 Hydralazine (100 μM) also decreases nitric oxide production and expression of inducible nitric oxide synthase (iNOS) in rat macrophages activated by LPS (Item Nos. 19660 | 19661) and interferon-γ (IFN-γ).3 It reduces contraction of rat aortic arterial strips induced by potassium and norepinephrine (Item No. 16673; IC50s = 2.2 and 3.06 mM, respectively).4 Hydralazine (2.6 mg/kg) lowers mean arterial blood pressure (MAP) by 41.76% in conscious rats.5 Formulations containing hydralazine have been used in the treatment of high blood pressure and heart failure.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cohn, J.N., McInnes, G.T., and Shepherd, A.M. Direct-acting vasodilators. J. Clin. Hypertens. (Greenwich) 13(9), 690-692 (2011).

    2. Cornacchia, E., Golbus, J., Maybaum, J., et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140(7), 2197-2200 (1988).

    3. Leiro, J.M., Alvarez, E., Arranz, J.A., et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int. Immunopharmacol. 4(2), 163-177 (2004).

    4. Orallo, F., Gil-Longo, J., Bardán, B., et al. Comparison of the effects of hydralazine and nifedipine on contractions and 45Ca influx of rat aorta. J. Pharm. Pharmacol. 43(5), 356-359 (1991).

    5. Siddiqui, A.A., Mishra, R., Shaharyar, M., et al. Triazole incorporated pyridazinones as a new class of antihypertensive agents: Design, synthesis and in vivo screening. Bioorg. Med. Chem. Lett. 21(3), 1023-1026 (2011).